Investigator: Gerard Criner, MD
This is a Phase 2 trial to evaluate the efficacy and safety of intravenous (IV) infusions of pamrevlumab as compared to placebo in hospitalized subjects with acute COVID-19 disease.
Investigator: Roberto Caricchio, MD
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
Investigator: Gerard Criner, MD
The purpose of this study is to evaluate the safety and tolerability, virologic efficacy, and clinical efficacy of REGN10933+REGN10987 compared to placebo in various instances.
Investigator: Jeffrey Stewart, MD
The primary objective of this study is to evaluate disease progression in spontaneously breathing COVID-19 patients receiving INOpulse® treatment. This is NOT a clinical trial. Rather, it is an investigational treatment made available through the FDA's Emergency Expanded Access program.
Investigator: Nina Gentile, MD
The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration.
Investigator: Arthur M. Feldman, MD, PhD
The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time blocking the development of cytokine storms or inhibiting cytokine-associated coagulopathy respectively.
